The Expanding Use of Continuous Glucose Monitoring in Type 2 Diabetes
Authors
Dabbagh, ZakeryMcKee, M Diane
Pirraglia, Paul A
Clements, Karen M
Liu, Feifan
Amante, Daniel J
Shukla, Prateek
Gerber, Ben S
UMass Chan Affiliations
Commonwealth MedicineFamily Medicine and Community Health
Medicine
Population and Quantitative Health Sciences
Document Type
Response or CommentPublication Date
2022-06-09
Metadata
Show full item recordAbstract
Over the last two decades, continuous glucose monitoring (CGM) has become a common self-monitoring strategy in type 1 diabetes (T1D). CGM, in which a minimally invasive, sensor-based device automatically measures and reports one's glucose levels up to every 5 min, improves hemoglobin A1c (HbA1c), reduces the frequency of dysglycemia, improves quality of life, and is cost-effective for people living with T1D compared to self-monitoring blood glucose (SMBG). CGM studies in type 2 diabetes (T2D) have been limited to date, especially those involving participants not requiring intensive insulin therapy.Source
Dabbagh Z, McKee MD, Pirraglia PA, Clements KM, Liu F, Amante DJ, Shukla P, Gerber BS. The Expanding Use of Continuous Glucose Monitoring in Type 2 Diabetes. Diabetes Technol Ther. 2022 Jul;24(7):510-515. doi: 10.1089/dia.2021.0536. Epub 2022 Jun 9. PMID: 35231190.DOI
10.1089/dia.2021.0536Permanent Link to this Item
http://hdl.handle.net/20.500.14038/51307PubMed ID
35231190ae974a485f413a2113503eed53cd6c53
10.1089/dia.2021.0536